Medivation AG

There appear to be two companies with similar names. The subject of the patent litigation is Medivation AG, a Swiss medical technology firm, which should not be confused with Medivation, Inc., a US-based pharmaceutical company acquired by Pfizer in 2016.

Medivation AG is a private company headquartered in Baden, Switzerland, founded in 2009. The company develops and manufactures medical products and provides engineering and medical certification services to partners, particularly startups. Medivation AG states it is ISO 13485 certified, a standard for quality management systems for medical devices. The company's own website does not provide information on its employee count or revenue.

The company's technology focuses on computer-assisted surgery, surgical navigation, medical imaging, and robotics. Its products and services include an optical tracking system for surgical navigation, patient-specific surgical technologies, AI-based image segmentation from CT scans, and statistical shape models for applications like implant design. Medivation AG serves startups, surgeons, and investors, and can act as a legal manufacturer for complete systems.

Based on the provided data, Medivation AG's patent litigation posture is that of an asserting party. It is listed as a plaintiff in its sole tracked case and has no record of being a defendant. This plaintiff-side activity is initiated by an operating company rather than a non-practicing entity (NPE), given the company's stated development and manufacturing operations.

The company's single tracked case is a 2026 suit filed in the District of New Jersey, Astellas US LLC et al. v. Dr Reddys Laboratories Ltd. In this case, Medivation AG is a co-plaintiff alongside Astellas, a pharmaceutical company that notably partnered with the separate US entity Medivation, Inc. on the drug Xtandi. The specific technology at issue in the New Jersey case is not detailed in the available data.